Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MGMT | P16455 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23683860 | 0.85 | GAA (0.37) | GAATSHRALDH1A1LMNAPOLB | |
| SCHEMBL12230452 | 0.83 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL21117958 | 0.77 | TSHR (0.35) | TSHRALDH1A1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL25280932 | 0.77 | MGMT (0.43) | GAACRBNMGMTALDH1A1POLB | |
| SCHEMBL16329449 | 0.77 | GAA (0.33) | GAACRBNMGMTPOLB | |
| SCHEMBL22657962 | 0.76 | CRBN (0.33) | GAACRBNMGMT | |
| SCHEMBL19725973 | 0.76 | CRBN (0.33) | GAACRBNMGMT | |
| SCHEMBL23194379 | 0.76 | CRBN (0.33) | GAACRBNMGMT | |
| SCHEMBL14981499 | 0.76 | CRBN (0.33) | GAACRBNMGMT | |
| SCHEMBL17319197 | 0.76 | CRBN (0.33) | GAACRBNMGMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235388-A1 | COMPOSITIONS AND METHODS FOR SEQUENCING USING AT LEAST ALTERING ELECTRICAL CHARACTERISTICS OF BRIDGES BETWEEN ELECTRODES | ILLUMINA SINGAPORE PTE. LTD. (SG) | 2023-07-27 | — | — | US | disclosed |
| US-20230235388-A1 | COMPOSITIONS AND METHODS FOR SEQUENCING USING AT LEAST ALTERING ELECTRICAL CHARACTERISTICS OF BRIDGES BETWEEN ELECTRODES | ILLUMINA SINGAPORE PTE. LTD. (SG) | 2023-07-27 | — | — | US | disclosed |
| US-11058775-B2 | Insulin dimer-incretin conjugates | MERCK SHARP & DOHME CORP. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | IAPP, GLP1R, GIPR | GAA 2441/4885CRBN 3719/4885TSHR 455/4885 |
| US-11058775-B2 | Insulin dimer-incretin conjugates | IAPP, GLP1R, GIPR | GAA 2441/4885CRBN 3719/4885TSHR 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.